Original Research
Published on 02 Sep 2022
Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China
in Heart Failure and Transplantation
- 3,925 views
- 7 citations